Non-Hodgkin's Lymphoma Perspective

 
 
  • 5 Things to Know About Chronotherapy With the 2017 Nobel Prize in Medicine being awarded to research on circadian rhythms, the time has come to take a look at synchronizing chemotherapy with the body's natural clock. Here are five things you should know about chronotherapy.
  • Cost Problem Only Getting Worse With IO Combos, Adjuvant Use   Drs Weber and Hamid discuss the increasing cost of immune-oncology therapy, particularly concerning as the number of patients using these agents in the adjuvant setting is likely to rise greatly.
  • EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  • IWMF 2018 Read clinically focused news coverage of key developments from IWMF 2018
  • 'Real World' CAR T Cells: Comparing and Using Approved Products   Drs Perales and Pasquini discuss the rapidly advancing field of CAR T and how patient safety and choice can be managed during these unprecedented times.
  • Comparing CAR T-Cell Therapies in Lymphoma   Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year.
  • Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  • European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  • Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  • Negative Trials, CAR T Studies Lead ASH Lymphoma Highlights   Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials.
  • Don't Miss Thyroid Disease in Kids Thyroid disease in children is surprisingly common -- and frequently missed. Dr Andrew Bauer provides key strategies to be sure these kids do not fall through the cracks.
  • ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment Dr Miguel-Angel Perales summarizes key recent developments in the field of CAR T cells and outlines the most important CAR T cell trials to follow at the 2016 ASH Annual Meeting.
  • No Lack of Enthusiasm for CAR-T Development, Experts Say Medscape Oncology asked a spectrum of researchers in the field to speculate on the implications of Novartis's decision to reintegrate cell therapy into its oncology unit.
  • Comorbidities in Inflammatory Joint Disease   Drs Paget and Schwartzman discuss both rare and common comorbidities, and the latest strategies to prevent their damaging effects.
  • Quiz: Which Presidential Candidates Had Health Issues? This isn't the first presidential election in which candidates' health has been scrutinized; can you remember the earlier cases?
  • A New Oncology Target: The Heart Delivering the most effective dose of chemotherapy without causing cardiotoxicity is a key goal of the emerging field of cardio-oncology. But are the current predictors of cardiotoxic risk adequate?
  • Malpractice Risk: The Dangers of False Positives An erroneous diagnosis borne from a misinterpreted test result can subject patients to unnecessary procedures, emotional trauma, and medical regimens that can alter their lives.
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • European Hematology Association (EHA) 2016 Congress Read clinically focused news coverage of key developments from EHA 2016.
  • Reducing Inequality With Precision Public Health   Eric Topol talks with Sue Desmond-Hellmann about her multidimensional career and how to scale precision medicine for global public health.